PD-1/PD-L1治疗非小细胞肺癌的研究进展

Research progress of PD-1/PD-L1 in the treatment of non-small cell lung cancer

程序性死亡受体-1(programmed cell death-1,PD-1)/程序性死亡配体-1(programmed cell death-ligand 1,PD-L1)信号通路与肿瘤免疫逃逸密切相关,针对PD-1/PD-L1通路的免疫检查点抑制剂为非小细胞肺癌(non-small cell lung cancer,NSCLC)患者提供了一种新的治疗选择,并且显示出良好的疗效和安全性。本文对PD-1/PD-L1抑制剂治疗NSCLC的临床研究进展进行综述。

The programmed cell death-1（PD-1）/programmed cell death-ligand 1（PD-L1） signaling pathway is closely related to the immune escape mechanism. Immune checkpoint inhibitors targeting PD-1/PD-L1 have become an important alternative for treating advanced non-small cell lung cancer（NSCLC） patients; NSCLC patients have shown considerable responses and good tolerance to these agents. The article reviews the current clinical researches on PD-1/PD-L1 for NSCLC treatment.